Sign in
4

Changes in Ownership

Ultragenyx Pharmaceutical Inc. Filed Acc 0001209191-21-054542

EVP and Chief Medical Officer sold 5,000 shares at an average $100.11 ($500,525)

  • EVP and Chief Medical Officer acquired 5,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Bedrosian Camille L · EVP and Chief Medical Officer

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2021-09-01 Exercise or conversion : show line 1 in the form +2,500 $55.00 $137,500 41,275 D
2021-09-01 Sale : show line 2 in the form −2,500 $100.03 $250,075 38,775 D
2021-09-02 Exercise or conversion : show line 3 in the form +2,500 $55.00 $137,500 41,275 D
2021-09-02 Sale : show line 4 in the form −2,500 $100.18 $250,450 38,775 D
Open-market sales · 5,000 sh · avg $100.11 · $500,525

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2021-09-01 Exercise or conversion : show line 5 in the form Stock Option (Right to Buy) −2,500 55,500 D
2021-09-02 Exercise or conversion : show line 6 in the form Stock Option (Right to Buy) −2,500 53,000 D
Loading xslF345X03/doc4.xml…